Pharma

  • Podcast promo image with a vintage microphone, featuring Almac and BioPharma Dive logos and the title “From Protocol to Patient: Inside Clinical Supply.”
    Image attribution tooltip
    Almac Clinical Services/BioPharma Dive
    Image attribution tooltip
    Sponsored by Almac Clinical Services

    [Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services

    This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.

    By BioPharma Dive's studioID • Updated May 26, 2026
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip

    Roche scraps two Ionis-partnered Huntington’s drugs

    The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.

    By • July 9, 2026
  • A stylized illustration of a pill breaking apart into smaller pills. Explore the Trendline➔
    Image attribution tooltip
    Brian Tucker / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Trendline

    Top 5 stories from BioPharma Dive

    Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

    By BioPharma Dive staff
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK ends brain drug alliance with Alector

    Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

    By • July 9, 2026
  • An AstraZeneca logo stands atop an office building in Shanghai, China.
    Image attribution tooltip
    Robert Way via Getty Images
    Image attribution tooltip
    China competition

    AstraZeneca, GSK intensify China ties with Sino Biopharm deals

    The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions in the U.S.

    By • July 8, 2026
  • A Novartis logo is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip

    Novartis to acquire ADC developer in a deal worth up to $1.5B

    The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.

    By • July 6, 2026
  • Exterior view of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group F. Hoffmann-La Roche
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roche KRAS drug succeeds in head-to-head lung cancer study

    The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.

    By Kristin Jensen • July 2, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program

    The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.

    By BioPharma Dive staff • June 30, 2026
  • A bottle of pills lays on top of a sheet of $100 bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Theravance, after clinical setbacks, agrees to $929M buyout

    The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.

    By • June 29, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services

    Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.

    By BioPharma Dive staff • June 26, 2026
  • Pill gavel
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    On second try, Acadia drug gets nod from European regulators

    The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.

    By • June 26, 2026
  • Pfizer's logo cast in metal.
    Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip

    Pfizer drug acquired in Seagen deal disappoints in lung cancer study

    The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.

    By • June 23, 2026
  • FDA magnifying glass
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    HHS, responding to China’s rise, moves to fast-track early drug research

    A series of newly planned reforms are designed to entice companies to start early trials in the U.S. rather than overseas.

    By • June 23, 2026
  • Medicine pill on 100 dollar banknote background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Hospitals irate after Eli Lilly follows through on 340B ultimatum

    The drugmaker stopped paying 340B discounts to hospitals that didn’t comply with its new paperwork requirements late last week. Hospitals are urging HRSA to step in.

    By Rebecca Pifer Parduhn • June 23, 2026
  • Pharmacist explaining to patient
    Image attribution tooltip
    Permission granted by Walgreens
    Image attribution tooltip
    Sponsored by Walgreens

    The first 14 days: How specialty programs set patients up for success

    As specialty medicines play a growing role in healthcare, the patient journey that follows is equally critical.

    June 22, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Neumora depression drug fails; EnGene to cut 50% of staff

    Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.

    By BioPharma Dive staff • June 16, 2026
  • Promotional graphic for Season 2 of The Progress Profile: Alzheimer’s Research in Focus, featuring the Pearson and BioPharma Dive logos on a dark blue background with abstract glowing blue wave patterns on the right.
    Image attribution tooltip
    William Walker/BioPharma Dive
    Image attribution tooltip
    Sponsored by Pearson

    [Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus

    This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.

    By BioPharma Dive's studioID • June 16, 2026
  • A piece of paper with the word "Medicare" emblazoned on a blue background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Medicare drug price rule may target under-the-skin Keytruda and Opdivo

    For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.

    By • June 15, 2026
  • An Eli Lilly logo is seen at the top of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Lilly scores early positive data for new JAK drug

    Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.

    By • June 15, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch

    New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.

    By BioPharma Dive staff • June 11, 2026
  • African American Woman With Itchy Skin. Allergy Or Psoriasis
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

    The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy. 

    By • June 11, 2026
  • Sanofi
    Image attribution tooltip
    Permission granted by Sanofi
    Image attribution tooltip

    Sanofi stops immune drug trial in latest research setback

    The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.

    By Kristin Jensen • June 10, 2026
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK boosts cancer pipeline with $11B Nuvalent buyout

    The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.

    By • June 9, 2026
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip

    Roche stakes $700M on Nurix’s protein-degrading drug

    Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.

    By • June 8, 2026
  • 3d DNA chain link
    Image attribution tooltip

    Shutterstock / DaveMF

    Image attribution tooltip
    Sponsored by Marken

    Precision under pressure: Logistic solutions for nuclear medicine scalability

    Racing the clock: How precision logistics deliver life-saving nuclear medicine.

    June 8, 2026
  • The outside of the U.S. Supreme Court with blue sky and clouds in the background.
    Image attribution tooltip
    Fintan Trimble via Getty Images
    Image attribution tooltip

    Generic drugmakers gain key victory in ‘skinny label’ patent case

    The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.

    By • June 5, 2026